Latest Market Exclusivity News

Syntara Limited has made significant strides in its clinical pipeline, launching new trials and receiving key regulatory designations, positioning 2026 as a pivotal year for the company.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.

Osteopore Limited has secured an exclusive agreement with MontsMed Hong Kong to introduce its innovative 3D-printed orthopaedic implants into Hong Kong, positioning itself strategically within the Greater Bay Area’s burgeoning medical market.

White Energy’s subsidiary BCBC has clinched an exclusive global agency agreement with Komarek to market briquettor machines using its proprietary BCB technology starting January 2026. This deal extends White Energy’s foothold in coal upgrading amid evolving energy markets.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

EBR Systems has expanded its intellectual property holdings with four new patents, reinforcing its lead in wireless cardiac pacing technology, while facing a preliminary setback on a patent term extension application.

Chimeric Therapeutics has won FDA Orphan Drug Designation for its CHM CDH17 CAR-T therapy targeting gastric cancer, advancing its clinical development with regulatory incentives and potential market exclusivity.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.